Cardiac Dimensions is a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company's initial technology platform, the CARILLON Mitral Contour System has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach. Cardiac Dimensions has operations in Kirkland, Washington; Sydney, Australia and Frankfurt, Germany.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/16/14 | $20,000,000 |
Lumira Capital M. H. Carnegie & Co. | undisclosed | |
| 10/08/14 | $8,500,000 |
Arboretum Ventures | undisclosed | |
| 03/11/15 | $15,200,000 |
Aperture Venture Partners Arboretum Ventures Life Sciences Partners Lumira Capital M. H. Carnegie & Co. | undisclosed | |
| 04/26/18 | $39,000,000 | Series B |
Aperture Venture Partners Arboretum Ventures Hostplus LSP Health Economics Fund Lumira Capital M. H. Carnegie & Co. Oxford Finance | undisclosed |
| 01/05/23 | $35,000,000 | Series D |
Arboretum Ventures EQT Life Sciences Horizon 3 Healthcare  Hostplus Lumira Ventures M. H. Carnegie & Co. | undisclosed |
